Evidence-based recommendations on nivolumab (Opdivo) for squamous cell carcinoma (SCC) of the head and neck in adults who have had platinum-based chemotherapy
Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma (BCC; non-melanoma skin cancer; rodent ulcers) in adults
Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults
Evidence-based recommendations on naltrexone–bupropion (Mysimba) for managing overweight and obesity in adults
Evidence-based recommendations on cladribine tablets (Mavenclad) for highly active relapsing–remitting multiple sclerosis (MS) in adults
Evidence-based recommendations on atezolizumab (Tecentriq) for untreated PD-L1-positive locally advanced or metastatic urothelial carcinoma in adults
Evidence-based recommendations on venetoclax (Venclyxto) for treating chronic lymphocytic leukaemia in adults
Evidence-based recommendations on ibrutinib (Imbruvica) for treating Waldenstrom's macroglobulinaemia (non-Hodgkin lymphoma) in adults after at least 1 therapy
Evidence-based recommendations on ceritinib (Zykadia) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC)
Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone receptor-positive, HER2-negative, locally advanced or
Evidence-based recommendations on ribociclib (Kisqali) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor
Evidence-based recommendations on golimumab (Simponi) for severe non-radiographic axial spondyloarthritis in adults
Evidence-based recommendations on cabozantinib (Cometriq) for treating medullary thyroid cancer (MTC) in adults
Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for adults with follicular lymphoma unresponsive to treatment with rituximab
Evidence-based recommendations on eluxadoline (Truberzi) for treating irritable bowel syndrome (IBS) with diarrhoea in adults
NICE is unable to make a recommendation about the use in the NHS of idelalisib with ofatumumab for treating chronic lymphocytic leukaemia because no evidence
NICE was unable to make a recommendation about the use in the NHS of methylnaltrexone bromide for treating opioid-induced constipation because no evidence was
Evidence-based recommendations on paclitaxel as albumin-bound nanoparticles (nab-paclitaxel) for untreated metastatic pancreatic cancer in adults
Evidence-based recommendations on dimethyl fumarate (Skilarence) for treating moderate to severe plaque psoriasis in adults
Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma (liver cancer) in adults
Evidence-based recommendations on cetuximab (Erbitux) for treating recurrent or metastatic squamous cell cancer of the head and neck in adults
Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune (idiopathic) thrombocytopenic purpura (ITP)
Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune (idiopathic) thrombocytopenic purpura (chronic ITP)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma in adults not previously treated with ipilimumab
Evidence-based recommendations on lenalidomide (Revlimid) for myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Evidence-based recommendations on ustekinumab (Stelara) for treating moderate to severe psoriasis in adults
Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer (NSCLC)
Evidence-based recommendations on lenalidomide (Revlimid) for the treatment of multiple myeloma in people who have received at least 2 prior therapies
Evidence-based recommendations on liposomal cytarabine–daunorubicin (Vyxeos) for untreated acute myeloid leukaemia (AML) in adults
Evidence-based recommendations on arsenic trioxide (Trisenox)for treating acute promyelocytic leukaemia (APML) in adults
Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C (HCV) in adults
Evidence-based recommendations on glecaprevir–pibrentasvir (Maviret) for treating chronic hepatitis C in adults
Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) in adults
Evidence-based recommendations on tofacitinib (Xeljanz) for treating moderate to severe rheumatoid arthritis (rheumatism) in adults
Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma after disease progression with ipilimumab in adults
Evidence-based recommendations on durvalumab (Imfinzi) for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
Evidence-based recommendations on brigatinib (Alunbrig) for treating ALK-positive advanced non-small-cell lung cancer in adults who have already had crizotinib
Evidence-based recommendations on tisagenlecleucel therapy (Kymriah) for treating relapsed or refractory diffuse large B-cell lymphoma in adults
Evidence-based recommendations on cochlear implants for children and adults with severe to profound deafness
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive cutaneous T-cell lymphoma in adults
Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults
Evidence-based recommendations on daratumumab (Darzalex) with bortezomib and dexamethasone for previously treated multiple myeloma in adults
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults
Evidence-based recommendations on dacomitinib (Vizimpro) for locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (NSCLC) in adults
Evidence-based recommendations on ribociclib (Kisqali) for hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in adults
Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults
Evidence-based recommendations on cemiplimab (Libtayo) for treating locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC) in adults
Evidence-based recommendations on letermovir (Prevymis) for preventing cytomegalovirus (CMV) disease after a stem cell transplant in adults
Evidence-based recommendations on sodium zirconium cyclosilicate (Lokelma) for treating hyperkalaemia (elevated blood potassium levels) in adults